<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Jeffrey A. Engelman(Cancer Research Center), Pasi A. Jänne(Harvard University), Neal I. Lindeman(Cornell University), Kreshnik Zejnullahu(Beth Israel Deaconess Medical Center), Courtney Hyland(Brigham and Women's Hospital), Joon Oh Park(Samsung Medical Center), Bruce E. Johnson(Harvard University), Lewis C. Cantley(Harvard University), Tony Mok(Chinese University of Hong Kong), Andrew M. Rogers(Beth Israel Deaconess Medical Center), James G. Christensen, Tetsuya Mitsudomi(Kindai University), Christopher-Michael Gale(Beth Israel Deaconess Medical Center), Xiao‐Jun Zhao(Tongji University), Charles Lee(Jackson Laboratory), Takayuki Kosaka(Beth Israel Deaconess Medical Center), Federico Cappuzzo(Ospedale di Livorno), Alison J. Holmes(Beth Israel Deaconess Medical Center), Youngchul Song(Beth Israel Deaconess Medical Center)
Cited by 4,459
Related Papers
A global reference for human genetic variation
|Nature|2015|19.9k
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k